Skip to main content
Targeting misfolded SOD1 to change the course of ALS

Because every moment matters for those living with ALS and those who care for them

About AL-S Pharma

AL-S Pharma is advancing AP-101, a first-in-class Phase 3-ready antibody that selectively targets toxic, misfolded SOD1 in both sporadic ALS and SOD1-ALS.

In 2025, the company completed a Phase 2 clinical trial of AP-101 with positive results. AL-S Pharma is advancing AP-101 into a confirmatory Phase 3 clinical trial planned to start in 2027.

About ALS

Amyotrophic lateral sclerosis (ALS) is a relentless and progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord. While symptoms vary from person to person, all forms ultimately lead to loss of independence and a markedly shortened lifespan.

About AP-101

AP-101 is a Phase 3-ready recombinant human antibody designed to selectively deplete toxic, misfolded forms of superoxide dismutase 1 (SOD1) while preserving the normal, protective function of healthy SOD1. AP-101 aims to slow the spread of SOD1 pathology and support the body’s natural clearance of harmful proteins.

«At AL-S Pharma, we are driven by the urgent need for effective therapies in ALS, a devastating neurodegenerative disease. The progress of AP-101 reflects our commitment to translating scientific innovation into clinical advances for people living with ALS and their families.»

Michael Salzmann, PhD
CEO

Explore the news & events


June 24, 2026
AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026
March 19, 2026
Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in…
June 24-26, 2026
European Network to Cure ALS (ENCALS) meeting 2026